BBI Group
http://www.the-bbigroup.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BBI Group
UK Studies More Antibody And Viral Test Options In COVID-19 Control Program
While COVID-19 testing capacity rises slowly the in UK, the scientific community is pressing to develop the range of test types to get the numbers up further to secure sustainable control of the disease.
Developing Antibody Tests Is Technically The Biggest COVID-19 Challenge Yet
The COVID-19 antibody tests that so far have gone through the validation process have not proven accurate enough to be rolled out for public use, says the UK. A new rapid test consortium is working on a solution.
Device/Diagnostics Quarterly Deal Statistics, Q3 2015
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
Medical Device Deals Update, August 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced June-July 2015.
Company Information
- Industry
- Research, Analytical Equipment & Supplies
- Services
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- BBI Diagnostics Group PLC
- Maine Biotechnology Services, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice